#Scinai Immunotherapeutics #Israel #Jerusalem #CDMO Services #BIO Convention 2025

Scinai Immunotherapeutics: New Funding and CDMO Growth

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a promising biopharmaceutical firm specializing in inflammation and immunology therapies, recently made headlines with its announcement of new funding and strategic growth in Contract Development and Manufacturing Organization (CDMO) services. CEO Amir Reichman is poised to leverage these advancements at the upcoming BIO International Convention 2025, taking place from June 16 to 19 in Boston.

Recent Funding Enhancing Operations

In a significant boost, Scinai has successfully raised $1.38 million through its Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors. This financial maneuver, which occurred at a volume-weighted average price of approximately $3.03 per American Depositary Share (ADS), represents a mere 3% discount to the market, completed without any warrants or fees. The infusion of funds is expected to fortify Scinai’s balance sheet and facilitate the advancement of both its CDMO endeavors and research & development programs. The company is now intensifying its supplier and partner engagement efforts to expedite its innovative nanobody pipeline toward IND-enabling studies, alongside expanding CDMO capacity and marketing outreach.

Rapid Growth in CDMO Services

Scinai's recent first-quarter results for 2025 indicate an impressive surge in CDMO revenues, reaching levels that nearly equaled the entire revenue for 2024 in just the first quarter. This robust demand has led to the company forecasting an annual revenue of approximately $2 million for 2025. Furthermore, Scinai anticipates achieving breakeven for its CDMO unit by the end of 2026, with a long-term revenue potential estimated at $12 million annually based on a single production shift, scalable with additional shifts as needed.

Cost Optimization for Financial Stability

In strides toward financial prudence, Scinai has embarked on a targeted cost-reduction initiative aimed at decreasing annual employment-related expenses by around $815,000. This crucial program seeks to lower operational burn rates, extend the financial runway, and enhance overall stability without compromising the talented personnel essential for progressing both its CDMO services and therapeutic research.

CEO’s Vision and Goals for BIO 2025

As Scinai heads into the BIO International Convention, CEO Amir Reichman expresses optimism about the company’s current momentum. He highlights the combined progress in funding, commercial traction in the CDMO business, and focused execution on research and development programs. He stated, "We’re proud of our progress and eager to forge new partnerships with pharmaceutical companies, CDMO customers, and investors."

During BIO 2025, Mr. Reichman plans to engage with pharma executives, institutional investors, and CDMO clients, showcasing Scinai’s recent achievements while exploring upcoming partnership opportunities.

For those interested in arranging meetings, Scinai can be contacted via the BIO partnering system or directly through their official email.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. operates on NASDAQ under the ticker symbol SCNI, offering two business segments: one focused on the internal development of biologic therapeutic products targeting inflammation and immunology, and another serving as a boutique CDMO that provides drug development services tailored for early-stage biotech companies. Scinai is committed to addressing substantial unmet medical needs with its innovative pipeline of nano-sized VHH antibodies (nanoAbs).

For more information, visit Scinai’s official website.